搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
STAT
17 小时
Pharmalittle: We’re reading about RFK Jr. and vaccines, obesity-drug prescribing for kids ...
Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...
19 小时
Novo Nordisk launches obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market.
21 小时
3 Things You Need to Know if You Buy Viking Therapeutics Today
There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...
2 天
Novo Nordisk readies trial results for next-generation weight-loss drug
The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...
2 天
5 new weight-loss drugs to watch in the fight for the next Ozempic
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
3 天
Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
Pharma and biotech stocks are down due to concerns over Robert F. Kennedy Jr. possibly taking the helm at HHS. Read more here ...
3 天
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
24/7 Wall St
4 天
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
4 天
on MSN
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies are looking to enter the space. Earlier this month, British pharma leader ...
5 天
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
来自MSN
6 天
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral ...
6 天
Amgen says no concerns around weight loss drug's bone density data after stock falls
Analysts chewed over early data showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈